文献速递肺栓塞与肺血管病

导管介入联合治疗与标准治疗在中高危肺栓塞中的随机先导试验

A Randomized Pilot Trial Comparing Combined Catheter-Interventional Treatment Versus Standard of Care in Intermediate High-Risk Pulmonary Embolism
RSS 订阅 · PubMed 高证据 · 肺栓塞 · 2026-07-19

该开放标签、单中心随机对照先导试验将20例中高危肺栓塞患者按2:1随机分配至联合导管介入治疗(CCIT,含局部纤溶与机械取栓)或指南导向标准治疗。主要终点为24小时后复合临床终点与右室/左室比值的变化,CCIT组两项均显著改善且安全性相似,但样本量小需更大规模试验验证。

要点

  • 中高危肺栓塞患者接受CCIT后24小时复合临床终点与RV/LV比值均较标准治疗显著改善。
  • CCIT组与对照组院内死亡及出血等安全性结局相似。
  • 该研究为先导试验,样本量仅20例,结论需更大规模试验确认。

核心结论

  • 在中高危肺栓塞患者中,联合导管介入治疗(局部纤溶联合机械取栓)较传统指南导向治疗有效且安全。

研究设计与样本

  • 开放标签、单中心、随机对照先导试验,20例中高危肺栓塞患者按2:1随机分配至CCIT组或对照组。

主要发现

  • 24小时后CCIT组复合临床终点改善0.02 ± 0.01,对照组无改善(-0.01 ± 0.01),组间比较p < 0.001。
  • 24小时后CCIT组RV/LV比值降低0.3 ± 0.2,对照组无变化(-0.1 ± 0.1),组间比较p = 0.02。
  • 包括院内死亡和出血在内的安全性结局在两组间相似。

关键数值与推荐

  • 复合临床终点由收缩压与心率的比值及呼吸频率构成,于随机化后24小时评估。
  • RV/LV比值通过经胸超声心动图于随机化后24小时评估。

临床怎么用

  • 对于中高危肺栓塞,可考虑在指南导向治疗基础上评估联合导管介入治疗的获益与安全性。
  • 该先导试验结果尚不足以改变常规实践,需等待更大规模试验确认。

局限性

  • 样本量仅20例,统计效能有限。
  • 单中心、开放标签设计可能引入偏倚。
  • 随访时间仅24小时,缺乏长期结局数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Catheter Cardiovasc Interv. 2026 Oct;108(4):1169-1175. doi: 10.1002/ccd.70758. Epub 2026 Jul 19. ABSTRACT BACKGROUND: Catheter-directed treatment of pulmonary artery embolism (PE) is increasingly used worldwide. Numerous devices for mechanical thrombectomy (MT) and local fibrinolysis (LF) have become available over recent years. While various studies show safety and efficacy for either MT or LF, little is known about the combination of both treatment modalities. AIMS: This open-label, single-center, randomized controlled pilot trial aimed to investigate the treatment effect size and safety of a combined catheter-interventional treatment (CCIT) approach for PE, consisting of LF and MT in comparison to conventional guideline-directed therapy. METHODS: Twenty patients with intermediate-high risk PE were randomized 2:1 to CCIT or control. The two co-primary endpoints were the difference in (1) a combined clinical endpoint (consisting of systolic blood pressure over heart rate, and respiratory rate) and (2) right-to-left ventricular (RV/LV)-ratio from a transthoracic echocardiogram between the two groups 24 h after randomization. RESULTS: After 24 h, the combined clinical endpoint improved by 0.02 ± 0.01 in the CCIT group, whereas no improvement was observed in the control group (-0.01 ± 0.01, p < 0.001 for between-group comparison). RV/LV-ratio was reduced by 0.3 ± 0.2 in the CCIT-group and remained unchanged in the control group (-0.1 ± 0.1, p = 0.02 for between-group comparison). Safety outcomes, including in-hospital mortality and bleeding, were similar between the two treatment groups. CONCLUSION: In this pilot study, CCIT of intermediate-high risk PE was found to be effective and safe in comparison to conventional PE treatment. These findings warrant confirmation in larger-scale trials. PMID: 42473023 | DOI: 10.1002/ccd.70758

来源:PubMed 高证据 · 肺栓塞,查看原文。版权归原作者所有。

引用

  1. PubMed 高证据 · 肺栓塞:A Randomized Pilot Trial Comparing Combined Catheter-Interventional Treatment Versus Standard of Care in Intermediate High-Risk Pulmonary Embolism

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。